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More and more limited financial resources in the health
care sector call for an economic evaluation of potential
new therapies. The economic evaluation of a new ther-
apy is complex and depends not only on the perspective
of the various stakeholders, but also on the country-
specific characteristics of various reimbursement sys-
tems. From the patient perspective, the costs for new
therapies might not be a concern, as long as the insur-
ance system covers the costs. From the hospital perspec-
tive, a new therapy which reduces the length of stay might
be worthwhile in a DRG-based reimbursement system, but
not in a pay-per-patient-day reimbursement system. To
respect the perspective of the society, a cost-effectiveness
analysis could be expressed in terms of a ratio where the
denominator is a gain in quality-adjusted life years
(QALY) and the numerator is the cost associated with the
health gain.
QALY is a measure of disease burden and takes into
account the quality of life measured as the Health Utility
Index (HUI, dead = 0 and perfect health = 1) and quan-
tity of life lived measured as survival time: QALY = survi-
val time × HUI (for example, 4 years survival with HUI
0.5 = 2 QALY, or 2 years survival with HUI 1 = 2 QALY).
Previous studies reported that mild therapeutic
hypothermia improves neurologic recovery and survival in
patients resuscitated from cardiac arrest. The estimated
number needed to treat is only six patients; nevertheless,
target temperature management has hardly been imple-
mented in post-cardiac arrest treatment. The aim of the
current study was to evaluate the cost-effectiveness of
therapeutic hypothermia in post-cardiac arrest patients.
The QALY–cost ratio was chosen as the primary outcome.
To assess the cost-effectiveness of temperature man-
agement, data from a Cochrane review about mild
hypothermia after cardiac arrest including 398 patients
were analyzed. The QALY–cost ratio was calculated
based on the cerebral performance score and total treat-
ment costs after cardiac arrest. The assumed costs
included potential cooling procedure, hospital stay, reha-
bilitation, and potential defibrillation implantation in
Austria.
Total treatment costs per 100 patients were €4.1
million for patients treated with mild hypothermia,
and €3.7 million for patients with standard care. Post-
arrest patients receiving mild hypothermia gained an
average of 1.11 QALY compared with conventional
care. This resulted in a cost-effectiveness ratio of
€3.827 per QALY.
Targeted temperature management at 32 to 34°C after
cardiac arrest seems to be a very cost-effective treat-
ment, with €3.827 per QALY far below commonly used
benchmarks for assessing the cost-effectiveness of an
intervention. These results may provide an economic
rationale for implementing targeted temperature man-
agement as a standard treatment after cardiac arrest.
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